Abstract
This study was designed to investigate the role of nitric oxide on catalepsy induced by fentanyl and haloperidol. Male albino mice were treated either with fentanyl (0.1-0.2 mg kg-1, s.c.) or haloperidol (0.5-2 mg kg-1, i.p.). The non-selective nitric oxide synthase inhibitor, NG-nitro-L-arginine (10 mg kg-1, i.p.), selective neuronal nitric oxide synthase inhibitor, 7-nitroindazole (3 mg kg-1, i.p.), and nitric oxide donors, L-arginine (30-300 mg kg-1, i.p.) and D-arginine (30 mg kg-1, i.p.), were applied 20 min prior to fentanyl or haloperidol injection. A mu-opioid receptor antagonist naloxone (1 mg kg-1, i.p.) was also given in some groups. The cataleptic status of mice was assessed by placing animals in a rearing position in the cage. If the mouse maintained cataleptic posture for more than 20 s, it was scored as cataleptic and duration of catalepsy was expressed in terms of minutes. Both NG-nitro-L-arginine and 7-nitroindazole prolonged fentanyl-induced catalepsy (fentanyl: 3.6+/-0.8 min; fentanyl+NG-nitro-L-arginine: 77.4+/-14.6 min, fentanyl+7-nitroindazole: 56.0+/-10.4 min; n=6; P<0.01). This effect was reversed by L-arginine and naloxone, but not by D-arginine. Nitric oxide synthase inhibitors also prolonged the catal...Continue Reading
References
Mar 1, 1977·The Journal of Pharmacy and Pharmacology·J MajA Rawlów
Jul 1, 1979·Neuropharmacology·C VanderWende, M T Spoerlein
Feb 7, 1977·European Journal of Pharmacology·C Ezrin-Waters, P Seeman
Jan 1, 1975·Psychopharmacologia·A WauquierH Lal
Jan 1, 1990·Annual Review of Pharmacology and Toxicology·L J Ignarro
Jul 1, 1968·British Journal of Pharmacology and Chemotherapy·U BanerjeeC A Goodrich
Aug 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·U HavemannK Kuschinsky
Oct 8, 1982·Neuroscience Letters·G S Ling, G W Pasternak
Apr 24, 1995·European Journal of Pharmacology·M S Starr, B S Starr
Dec 12, 1994·Brain Research·T AbekawaT Koyama
Apr 13, 1995·European Journal of Pharmacology·C SandiC Guaza
Jan 1, 1995·Brain Research Bulletin·N T SandorB Lendvai
Nov 24, 1995·European Journal of Pharmacology·Y NodaT Nabeshima
Dec 29, 1995·Neuroreport·R A MarrasF S Guimarães
Sep 26, 1996·European Journal of Pharmacology·S W ChenG H Loew
Oct 23, 1997·Behavioural Brain Research·E DzoljicM R Dzoljic
Jan 1, 1997·Fundamental & Clinical Pharmacology·R L Büyükuysal
Jan 1, 1997·Fundamental & Clinical Pharmacology·R L Büyükuysal
Mar 24, 1998·Brain Research Bulletin·G Segovia, F Mora
Mar 28, 1998·Neuropharmacology·A R West, M P Galloway
Mar 28, 1998·Neuropharmacology·B J MorrisA M Nolan
Aug 1, 1998·Brain Research·L P Liang, S Kaufman
Aug 12, 1998·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J G PiresH A Futuro-Neto
Mar 19, 1999·Neuroscience Letters·C DesvignesL Lambás-Señas
Feb 15, 2000·Psychopharmacology·E A Del Bel, F S Guimarães
Apr 12, 2000·Journal of Neurophysiology·A R West, A A Grace
Apr 21, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·T ArakiY Itoyama
Dec 6, 2001·European Journal of Pharmacology·O P Dall'IgnaD R Lara
Dec 12, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·E A AfifyM S Abou Zeit-Har
Mar 6, 2002·Methods and Findings in Experimental and Clinical Pharmacology·M GuptaP Pandhi
Apr 23, 2002·Psychopharmacology·E A Del BelL P Nucci-da-Silva
Dec 9, 2003·European Journal of Pharmacology·Mohammad-Reza ZarrindastAli Haeri-Rohani
Mar 18, 2004·Experimental Neurology·Valentina BashkatovaWerner J Schmidt
Jun 10, 2004·Neurochemistry International·János P KissE Sylvester Vizi